alexa
Reach Us +1-217-403-9671
BIOEQUIVALENCE STRATEGIES FOR ONCOLOGY PRODUCTS | 8421
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

BIOEQUIVALENCE STRATEGIES FOR ONCOLOGY PRODUCTS

International Conference & Exhibition Bioequivalence and Bioavailability

Dr. Shivprakash Rathnam

ScientificTracks Abstracts: J Bioequiv Availab

DOI: 10.4172/0975-0851.1000001

Abstract
T he mortality due to cancer is huge and the treatment is very costly. Generic drugs are necessary now to reduce the cost of treatment and make medicines available to the needy at affordable costs. Developing generic versions of oncology products involves huge costs and risks. Many challenges are to be faced and strategies to be adopted to conduct bioequivalence of oncology products. Conducting BE studies for these products are not as simple and straight forward as other products. Strategies are to be adopted from protocol development, recruitment of patients to conduct of clinical study and regulatory requirements. These molecules are various types and act through various mechanisms and have their unique adverse effects. There are many ethical issues concerning using normal subjects and patients for these studies. Various designs options are to be adopted based n the formulation whether it is injection, infusion, oral or entrapped liposomal and nanoparticle formulations. The above issues will be discussed in the presentation.
Biography
Relevant Topics
Top